Dabigatran etexilate

Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin) . Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation[1].

Product Specifications

CAS Number

[211915-06-9]

Product Name Alternative

BIBR 1048

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Thrombin

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Dabigatran-etexilate.html

Concentration

10mM

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N(C1=NC=CC=C1)CCC(OCC)=O)C2=CC=C3C(N=C(N3C)CNC4=CC=C(C(NC(OCCCCCC)=O)=N)C=C4)=C2

Molecular Formula

C34H41N7O5

Molecular Weight

627.73

Precautions

H302, H315, H319, H335

References & Citations

[1]Wienen W, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally activeprodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98 (1) :155-62.|[2]Blair HA, Keating GM. Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation. Drugs. 2017;77 (3) :331-344.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Biochem Pharmacol. 2016 Nov 1:119:76-84.|Elife. 2022 Mar 23:11:e77444.|J Nanobiotechnology. 2025 Nov 20;23 (1) :724.|J Chromatogr Sci. 2016 Jul 29;54 (9) :1648-1651.